Replies to post #275443 on Anavex Life Sciences Corp (AVXL)

[XenaLives]

GOOD POINT - The following is a quote from J&J's page on the subject, link is to full page. It seems this may be a problem now.

Pharmaceutical and Medical Devices Product Pipeline Information
The following information regarding the pipeline of new drugs (including line extensions) and medical devices may be disclosed:

-Chemical or device name
-Brand name (if available)
-Indication
-Patent expiration date
-Clinical stage (if appropriate)
-Mechanism of action
-Market size/market factors
-Previously published clinical trial data

Specific projected regulatory filing dates or estimated approval dates for any products, regardless of stage, should not be disclosed (except that general timing, such as year or quarter, for select new molecular entities may be appropriate to disclose). For Pharmaceuticals, the Company's policy is generally to highlight only those products that are in Phase III clinical and beyond. Products in Phase II clinical stage and earlier are generally higher risk and typically many years from the marketplace and generally should not be discussed. Public disclosure related to the Pipeline will take place at key points in the development process (e.g., entering Phase III or a regulatory filing) and will be made in compliance with Regulation FD.

https://www.investor.jnj.com/guidelines.cfm